AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Tso500 local app12/31/2022 ![]() ![]() ![]() SBS4 was significantly more present in early stages (I and II) versus advanced stages (III and IV P = .005). SBS2 and/or SBS13, both associated with activity of the AID/APOBEC family of cytidine deaminases, were observed in 11 of 76 samples (14%). SBS signature 4 (SBS4), associated with tobacco smoking, was prominently present in 25 of 76 samples (33%). Mutational signatures were evaluated in 76 tumor samples (39% median TMB 15.2 mut/Mb). Median total TMB was 10.3 mut/Mb (range 0–109.3). Mutational signature profiling was performed on tumor samples in which at least 30 somatic single base substitutions (SBS) were detected. On each sample TMB was determined and defined as the total number of single nucleotide mutations per Mb (mut/Mb) including non-synonymous mutations. The samples were sequenced using a 2 megabase (Mb) gene panel. In this retrospective study, we studied tumor DNA from patients with non-small cell lung cancer (NSCLC) irrespective of stage. Here we set out to investigate particular mutational processes by assessing mutational signatures and associations with clinical features, tumor mutational burden (TMB) and targetable mutations. Mutational signatures harbor potential clinical value as predictors of therapy response in cancer. The development of predictive and prognostic biomarkers is of great importance. With the growing number of targeted therapies and the introduction of immuno-oncology (IO), personalized medicine has become standard of care in patients with metastatic disease. Lung cancer is the leading cause of cancer death worldwide. ![]()
0 Comments
Read More
Leave a Reply. |